Factor VII Clotting Assay: Influence of Different Thromboplastins and Factor VII-Deficient Plasmas

Summary

Being a putative predictor of ischemic heart disease, the measurement of factor VII (FVTI) coagulant activity will be presumably requested to clinical laboratories with increasing frequency. To assess the influence on FVII assays of different thromboplastins and FVII-deficient plasmas we compared performances of all possible combinations of 5 thromboplastins and 6 deficient plasmas. The reproducibility of the clotting times of the dose-response curves for human and rabbit thromboplastins were acceptable (CV lower than 7%), whereas bovine thromboplastin had a higher CV. Reproducibility was very similar for all deficient plasmas when they were used in combination with a given thromboplastin. Responsiveness of the dose-response curve did not depend on the deficient plasma but rather on the thromboplastin: one rabbit thromboplastin was the least responsive, the bovine thromboplastin the most responsive, the human and the remaining two rabbit thromboplastins had intermediate responsiveness. Assay sensitivity to cold-activated FVII varied according to the thromboplastin: the bovine thromboplastin was the most sensitive, the human thromboplastin the least sensitive, of the three rabbit thromboplastins two were relatively sensitive, one was almost insensitive. In conclusion, our results indicate that thromboplastin rather than deficient plasma is the crucial factor in the standardization of FVII assay.

• References

• 1 Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; 2: 461
• 2 Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. J Am Med Assoc 1987; 1258: 1183-1186
• 3 Meade TW, North WRS, Chakrabarti RR, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050-1054
• 4 Meade TW, Mellows S, Brozovic M, Miller SG, Chakrabarti RR, North WR S, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 5 Wilhelmsen L, Svardsudd K, Korsan-Bengtssen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 6 Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW. Association between dietary fat intake and plasma factor VII coagulant activity. A predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-277
• 7 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alfa-VIIa in hyperlipidaemia, with possible implications for ischemic heart disease. Br J Haematol 1987; 59: 249-258
• 8 Scarabin PY, Bara I, Samana M, Orssaud G. Further evidence that activated factor VII is related to plasma lipid. Br J Haematol 1985; 61: 177-184
• 9 Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications; Oxford: 1972: 629-647
• 10 Brandt JT, Triplett DA, Fair DS. Choice of substrate plasma: the emerging role of immune-depleted substrate plasmas for one-stage coagulation factor assays. In: Advances in Coagulation Testing: Interpretation and Application. Triplett DA. (ed). College of American Pathologists; Skokie, IL: 1986: 1-8
• 11 Brandt JT, Triplett DA, Fair DS. Characterization and comparison of immune-depleted and hereditary factor VII-deficient plasmas as substrate plasmas for factor VII assay. Am J Clin Pathol 1986; 85: 583-589
• 12 Kleinbaum DG, Jupper LL, Muller KE. (eds). Applied Regression Analysis and Other Multivariable Methods. PWS-Kent Publishing Company; Boston, MA: 1988: 260-296
• 13 van Deijk WA, van Dan-Mieras MCE, Muller AD, Hemker HC. Evaluation of a coagulation assay determining the activity state of factor VII in plasma. Haemostasis 1983; 13: 192-197
• 14 Kitchen S, Malia RG, Greaves M, Preston FE. A method for the determination of activated factor VII using bovine and rabbit brain thromboplastins: demonstration of increased levels in disseminated intravascular coagulation. Thromb Res 1988; 50: 191-200
• 15 Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med 1988; 111: 475-481
• 16 Orlando M, Leri O, Macioce G, Mattia G, Ferri GM. Factor VII in subjects at risk for thromboembolism: activation or increased synthesis?. Haemostasis 1987; 17: 340-343